SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc. (NYSE: DNA) announced today that it has settled its patent litigation with MedImmune, Inc. involving the Cabilly patent (U.S. Patent No. 6,331,415), which is co-owned by Genentech and City of Hope and relates in part to methods of producing antibodies.